Release date- 29082019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the expanded use of the VENTANA PD-L1 (SP142) Assay3,4 in triple-negative breast cancer
(TNBC) for patients living in CE (Conformite Europeenne) markets where the Roche cancer immunotherapy medicine Tecentriq is approved.
M2 PRESSWIRE-August 29, 2019-: European Commission approves Roche's Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer
Roche is launching Ventana PD-L1, a companion diagnostic used to identify triple-negative breast cancer
patients eligible for treatment with Roche's cancer immunotherapy treatment Tecentriq.
TUESDAY, July 16, 2019 (HealthDay News) -- The odds of diagnosis of triple-negative breast cancer
(TNBC) are increased for non-Hispanic black and Hispanic women and for younger women, according to a study published online July 8 in Cancer.
"Among them, the development of a new formulation of EGRIFTA in NASH-HIV which, based on early market research, represents an estimated total population between 100,000 to 300,000 patients, and our targeted oncology platform for which we will pursue two initial indications in ovarian and triple-negative breast cancer
The researchers uncovered a significant burden of triple-negative breast cancer
for women of colour, specifically non-Hispanic black women, and for younger women.
Effect of honey in improving breast cancer treatment and gene expression modulation of MMPs and TIMPs in Triple-Negative Breast Cancer
M2 PHARMA-May 22, 2019-US Merck Provides Update on Phase 3 KEYNOTE-119 Study of Keytruda Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer
The company added that the US Food and Drug Administration (FDA) has approved the immunotherapy TECENTRIQ in combination with Abraxane as frontline therapy for PD-L1-positive, unresectable locally advanced or metastatic triple-negative breast cancer
In a clinical trial involving 108 women with triple-negative breast cancer
that had spread around the body, the infused drug caused "significant" tumour shrinkage, researchers reported.
In laboratory tests the protein, Tinagl1, held back the growth and spread of triple-negative breast cancer